Rick Livesey

@ricklivesey.bsky.social

Cellular and molecular neuroscience, neurodegeneration & drug discovery. Founder and CEO of Talisman Therapeutics & Gen2 Neuroscience, honorary prof at UCL. Cambridge UK.

*new publication announcement* our first CRISPR screen paper is now out as Open Access in EMBO Journal. We find an unexpected role for LRRK2, an important gene/protein in Parkinson's disease, in controlling the uptake of both tau and synuclein by human neurons www.embopress.org/doi/full/10....

Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2 | The EMBO Journal

imageimageNeuronal uptake of extracellular tau protein is thought to propagate intracellular protein aggregation between neurons, contributing to the pathogenesis of Alzheimer’s and other neurodegener...

embopress.org

Now up, positively our lab's last word on Ptbp1. Developmental loss of function Ptbp1 turns out not to regulate neurogenesis or cell fate specification at all, but does alter splicing patterns and slightly accelerates expression of photoreceptor-specific genes./1 www.biorxiv.org/content/10.1...

Ptbp1 is not required for retinal neurogenesis and cell fate specification.

The RNA-binding protein Ptbp1 has been proposed as a master regulator of neuronal fate, repressing neurogenesis through its effects on alternative splicing and miRNA maturation. While prior studies us...

biorxiv.org

Today I have resigned from my position as a Data Editor at Proceedings B. I believe the journal does great work, but it feels wrong to voluntarily spend my time holding authors to account on behalf of the Royal Society, while the Society refuses to hold its own Fellows to account.

Today is International Trans Day of Remembrance. This is the toughest time in history to be trans and visible in the world, thanks to certain politicians, billionaires, trash media and Evangelicals. And it’s particularly tough for children and teens. Now, more than ever, we need our allies. Ty ❤️🏳️‍⚧️🏳️‍🌈

Bild

Just finding my way on this platform and finding some friends old and new. Mainly preoccupied with protein kinase signalling pathways, how they work & what they do. Group Leader and Director of the Babraham Institute, which is home to my brilliant colleagues in Signalling, Epigenetics and Immunology

With the big science migration finally underway to bsky, I've finally deactivated my legacy account on the other site. Content and contacts here have improved greatly in recent weeks, no more need to sift through the toxic garbage over on the bird site to find thoughtful posts etc.

Interesting arguments on how to go about target ID and validation to ensure higher rates of success in drug development. Broadly v much agree - although defining what constitutes causal human biology (and genetic evidence for targets) could do with further refinement, not least in neurology.

David Shaywitz@dshaywitz.bsky.social · 2y ago

"Causal Human Biology": great unlock for biopharma R&D - or le mot du jour, bereft of meaning through exuberant overuse? For Vertex, at least, this phrase+approach seems to really mean something, as I discuss in my latest column: timmermanreport.com/2024/10/can-.... #biosky @dereklowe.bsky.social

Open letter from a group of sleuths re problems with editors/papers at Scientific Reports deevybee.blogspot.com/2024/10/an-o... They've published 23K papers in 2024 with APC of £2090, raising £48 million from this journal alone, so should be able to put resource into cleaning this up.

An open letter regarding Scientific Reports

16th October 2024  to: Mr Chris Graf Research Integrity Director, Springer Nature and Chair Elect of the World Conference...

deevybee.blogspot.com